Is Iovance Biotherapeutics Stock a Buy?

These are exciting times to be an Iovance Biotherapeutics (NASDAQ: IOVA) shareholder. The biotech has made encouraging clinical and regulatory progress in the past year. Its most important product is helping it generate strong revenue growth, and although it has been a bit of a wild and volatile ride, its shares have performed much better than the broader market over the trailing 12-month period.It might be worth investing in the stock if the company can maintain this momentum. Let's find out whether that's the case, or if it's best to avoid Iovance.Iovance Biotherapeutics is an oncology specialist. The company's platform focuses on tumor-infiltrating lymphocytes (TILs), a type of immune cell that can recognize and kill cancer cells. Iovance's TIL-based cancer therapies work by removing a patient's own TILs, creating personalized treatments, and reinserting them into the patient.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool